CJC-1295 (no DAC): Modified GHRH Analog

Research on the stabilized growth hormone releasing hormone analog

Source: https://indexalabs.com/blog/cjc-1295-no-dac-ghrh-analog Abstract: CJC-1295 without DAC (Drug Affinity Complex) is a modified GHRH analog with enhanced stability and potency. This guide covers its mechanism, advantages over native GHRH, and research applications.

1. Overview

CJC-1295 (no DAC), also known as Mod GRF 1-29, is a modified version of the first 29 amino acids of GHRH with four amino acid substitutions that increase stability and reduce enzymatic degradation. The “no DAC” version lacks the Drug Affinity Complex, providing a shorter half-life suitable for pulsatile GH release.

2. Structural Modifications

2.1 Enhanced Stability Four amino acid substitutions protect against DPP-IV enzymatic cleavage.

2.2 GHRH Receptor Affinity Maintains full agonist activity at the GHRH receptor.

2.3 Half-Life Considerations Without DAC: ~30 minutes (allows pulsatile release) With DAC: ~8 days (constant elevation)

2.4 No DAC Advantage Shorter half-life better mimics natural GHRH pulsatility.

3. Mechanisms of Action

3.1 Pituitary Stimulation Binds GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release.

3.2 Synergy with Ghrelin Pathway Combining with GHRP (Ipamorelin) creates synergistic GH release.

3.3 Preserved Feedback Maintains normal hypothalamic-pituitary feedback regulation.

4. Research Protocols

4.1 Available Sizes CJC-1295 (no DAC) is available in 5mg and 10mg vials, and combined with Ipamorelin.

4.2 Timing Optimal administration aligns with natural GH secretion (evening/night).

4.3 Combination Protocols Most effective when combined with a GHRP like Ipamorelin.